Biotech / Finance

Array Biopharma's 12\% Drop, Explained

From Biotech
March 20, 2017 - 9:25am
Shares of Array Biopharma Inc (NASDAQ: ARRY), a biopharmaceutical company that focuses on drugs to treat patients suffering from cancer, lost more than 12 percent early Monday morning after announcing a disappointing update to one of its therapies. Array Biopharma announced in a press release that the new drug application (NDA) for its binimetinib monotherapy for the treatment of a rare subset of skin cancer has been withdrawn from the U.S. Food and Drug Administration's (FDA) Division ...Full story available on Benzinga.com


Continue reading this article »